Axitinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoid Tumor

Conditions

Carcinoid Tumor

Trial Timeline

Oct 25, 2011 → Feb 13, 2018

NCT ID

NCT01435122

About Axitinib

Axitinib is a phase 2 stage product being developed by Pfizer for Carcinoid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT01435122. Target conditions include Carcinoid Tumor.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03839498	Phase 2	Active	Jan 22, 2019	Feb 1, 2027	Pheochromocytoma
NCT02156895	Pre-clinical	Completed	Jul 17, 2018	Aug 6, 2021	Advanced Renal Cell Carcinoma
NCT01798446	Phase 2	Completed	Feb 1, 2013	Dec 1, 2016	Renal Cell Carcinoma
NCT01693822	Phase 2	Completed	Oct 1, 2012	Feb 28, 2022	Clear-cell Metastatic Renal Cell Carcinoma
NCT01649180	Phase 2	Terminated	Jul 1, 2012	Mar 1, 2016	Renal Cell Carcinoma
NCT01540526	Phase 1	Completed	Mar 1, 2012	Dec 1, 2014	Solid Malignancies
NCT01473043	Pre-clinical	Completed	Mar 1, 2012	Mar 1, 2014	Renal Cell Carcinoma
NCT02597322	Phase 2	Completed	Feb 1, 2012	Jun 1, 2017	cT2a N0NxM0 Renal Tumor
NCT01321437	Phase 2	Completed	Dec 1, 2011	Dec 1, 2016	Melanoma
NCT01435122	Phase 2	Completed	Oct 25, 2011	Feb 13, 2018	Carcinoid Tumor
NCT01508117	Phase 2	Terminated	Aug 1, 2011	Oct 1, 2012	Glioblastoma Multiforme
NCT01263769	Phase 2	Completed	Feb 1, 2011	Jun 5, 2023	Kidney Cancer
NCT01255137	Phase 2	Completed	Sep 1, 2010	Dec 1, 2012	Adrenal Cortex Neoplasms
NCT01140737	Phase 2	Completed	Aug 31, 2010	Jan 8, 2019	Soft Tissue Sarcoma
NCT00094094	Phase 2	Completed	Feb 1, 2005	Jul 1, 2007	Lung Neoplasms

Competing Products

20 competing products in Carcinoid Tumor

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab + Somatostatin Analog	Eli Lilly	Phase 2	52
Pasireotide	Novartis	Phase 1	33
Pasireotide + Octreotide	Novartis	Phase 3	77
Pasireotide (SOM230)	Novartis	Phase 2	52
Octreotide + Placebo + Everolimus	Novartis	Phase 3	77
Lutathera	Novartis	Phase 2	52
EPO906 epothilone B	Novartis	Phase 2	52
Panitumumab	Amgen	Phase 2	51
Lanreotide + Placebo (for sunitinib) + Sunitinib	Pfizer	Phase 2	51
Nivolumab + Cabozantinib	Bristol Myers Squibb	Phase 2	51
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin	Sanofi	Phase 2/3	64
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)	Ipsen	Phase 3	74
lanreotide (Autogel formulation)	Ipsen	Approved	82
Lanreotide + Placebo	Ipsen	Phase 3	74
BIM 23A760	Ipsen	Phase 2	49
Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine	Crinetics Pharmaceuticals	Phase 2	47
Paltusotine + Placebo	Crinetics Pharmaceuticals	Phase 3	72
Telotristat etiprate + Placebo-matching telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	72
Telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	72
500 mg [14C]-LX1606	Lexicon Pharmaceuticals	Phase 1	28

Other Products from Pfizer